Sirdupla: new LABA/corticosteroid inhaler

Sirdupla (salmeterol/fluticasone) has been launched for use in adults with asthma where a long-acting ß2-agonist and inhaled corticosteroid is appropriate.

Sirdupla (salmeterol/fluticasone) is a bioequivalent alternative to Seretide Evohaler.
Sirdupla (salmeterol/fluticasone) is a bioequivalent alternative to Seretide Evohaler.

The metered-dose inhaler is available in two strengths:

  • 25/125 (salmeterol 25 microgram, fluticasone propionate 125 microgram)
  • 25/250 (salmeterol 25 microgram, fluticasone propionate 250 microgram)

Further information
View Sirdupla drug record 
Summary of Product Characteristics
Manufacturer: Mylan

Sirdupla can be used in patients over 18 years of age not adequately controlled with inhaled corticosteroids and an 'as needed' inhaled short-acting β2-agonist, and in those already adequately controlled on both an inhaled corticosteroid and a long-acting β2-agonist.

The efficacy and safety of salmeterol and fluticasone for the treatment of asthma are well established.

Prescribers should note that only the AeroChamber Plus spacer device should be used with Sirdupla. 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

First oral GLP-1 agonist launched for type II diabetes

First oral GLP-1 agonist launched for type II diabetes

Prescribers can now consider a GLP-1 agonist as an...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Don't prescribe analgesics for chronic pain, new NICE guidance advises

Don't prescribe analgesics for chronic pain, new NICE guidance advises

Draft NICE guidance on chronic pain warns that prescribing...